Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Investor group plans to take Chinese pharmaco Simcere private; finalized at $122mm.

Executive Summary

Simcere Pharmaceutical Group’s founder and chairman Jinsheng Ren, plus a company he controls, New Good Management, along with Assure Ahead Investments (owned by Hony Capital) and its affiliates have sent Simcere a nonbinding proposal to acquire approximately 44.6% of the shares of the public Chinese pharmaco that they don’t already hold for $238mm, or $9.56 per ADS (a 20% premium). Simcere has put together a special committee to evaluate the offer.
Deal Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
    • Vaccines
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Contract
    • Buy-out
    • Payment Includes Cash
    • Partial Acquisition

Related Companies